Colchicine
In brief
- Colchicine is a prescription-only medicine (POM) in the UK.
- Colchicine is used for acute gout flares, prevention of recurrent gout, familial Mediterranean fever, and sometimes pericarditis. It works by reducing inflammation, especially by inhibiting neutrophil activity and the inflammatory response to uric acid crystals.
- The usual dose depends on the condition: for an acute gout flare, 500 micrograms two to four times daily until symptoms are relieved (maximum 6 mg per course); for prevention of gout, 500 micrograms once or twice daily; for familial Mediterranean fever, typically 1.2–2.4 mg per day in divided doses; for pericarditis, 0.5 mg once or twice daily.
- Colchicine is usually taken by mouth as tablets, and in rare cases as an oral solution.
- It usually starts to work within 1–2 hours for acute gout symptoms, although full relief may take longer depending on the condition being treated.
- The duration of action is generally several hours for symptom control, but treatment for prevention may be continuous over months or longer as directed by a clinician.
- Alcohol should be avoided or kept to a minimum, especially during gout attacks, as it can worsen gout and increase gastrointestinal irritation.
- The most common side effects are diarrhoea, nausea, abdominal pain, and vomiting.
- Would you like to try colchicine without a prescription?
Basic colchicine information
- INN (international nonproprietary name): Colchicine
- Brand names available in the United Kingdom: generic colchicine 500 microgram tablets.
- ATC code: M04AC01
- Forms and dosages: tablets 500 micrograms (0.5 mg).
- Manufacturers in the United Kingdom: various generic manufacturers.
- Registration status in the United Kingdom: approved and listed as prescription only under MHRA oversight.
- OTC / Rx classification: Prescription-only medicine (POM).
Colchicine in the UK
In the UK, colchicine is an MHRA-approved prescription-only medicine. It is supplied as generic 500 microgram (0.5 mg) tablets, usually in blister packs. It is not an over-the-counter product: the prescription and strength are checked before supply, and a suitable generic colchicine equivalent is dispensed where permitted.
Prescription route
An NHS prescription is the standard route for many patients, especially when colchicine is prescribed for gout or a specialist indication; it may be issued by a GP, rheumatology or hospital team.
What colchicine is and why it is prescribed
Colchicine is a prescription antigout medicine used in musculoskeletal conditions, especially when a doctor wants to control inflammation rather than lower uric acid.
It is an old medicine, but it remains relevant because it still has an important role in gout medicine, Familial Mediterranean Fever and some specialist inflammatory conditions.
- INN
- International Nonproprietary Name for the active substance: colchicine.
- ATC
- Classified as M04AC01, within the musculoskeletal system and antigout preparations.
- Antigout
- A medicine used to treat or prevent gout symptoms, especially gout flares.
In pharmacy terms, colchicine tablets are prescribed drugs with a narrow margin for error, so dose and interactions matter.
That is one reason prescriptions are checked carefully for dose and interactions.
Definition and medicine class
Colchicine is the INN used internationally, and the medicine belongs to the antigout group.
It does not work by changing uric acid metabolism, which separates it from allopurinol, febuxostat and other urate-lowering treatments.
ATC code and how it is categorised
The ATC code M04AC01 places it in the musculoskeletal system and antigout preparations with no effect on uric acid metabolism.
That classification helps pharmacists and prescribers distinguish it from medicines that lower urate over time.
Why it remains relevant despite older age
Older medicines sometimes survive because they still do the job well, and colchicine is a good example.
It is still commonly used for gout flare treatment, gout prevention and FMF treatment, with additional specialist use in pericarditis.
How colchicine works in the body
Patients often want to know why it helps so quickly in a flare but is not the same as long-term urate control.
Colchicine is anti-inflammatory, and its effect is linked to reducing neutrophil activity, which is part of the inflammatory cascade in gout and FMF.
That is why timing matters when treating a gout flare.
| Inflammation step | What colchicine does | Why timing matters |
|---|---|---|
| Crystal-triggered inflammation | Helps calm the inflammatory response | Works best when taken early in an acute gout flare |
| Neutrophil activity | Reduces inflammatory cell movement and activation | Useful in gout flare and FMF treatment |
| Long-term prevention | Supports prophylaxis when used regularly | Not a replacement for urate-lowering therapy |
In acute gout, the medicine is most useful when taken at the first sign of pain and swelling.
For FMF and pericarditis, the aim is more continuous inflammation control rather than a one-off rescue effect.
It is not urate-lowering therapy, so it does not remove the underlying uric acid problem that may be driving gout.
Inflammation control in gout and FMF
The main clinical benefit is suppression of the inflammatory response that causes pain, redness and swelling.
That makes it useful both for acute gout and for prevention in people with recurrent flares.
Why timing matters for acute flare treatment
Patients sometimes wait until the flare is severe, but the medicine is generally best started early.
Delayed use can mean a slower response.
Why it is not the same as urate-lowering therapy
Allopurinol and febuxostat reduce uric acid, whereas colchicine does not.
That difference matters because colchicine cannot replace long-term gout control.
Who colchicine is for in real-world practice
In practice, the people asking for colchicine usually fall into a few clear groups.
Some are dealing with recurrent gout flares, some need prevention, and others have a specialist diagnosis such as Familial Mediterranean Fever.
A smaller group may be receiving it off-label under hospital supervision.
- Adults with acute gout who need rapid flare treatment.
- Adults with recurrent flares who need gout prevention.
- Patients diagnosed with Familial Mediterranean Fever.
- People with pericarditis where a specialist has chosen colchicine.
- Selected patients in cardiovascular research or specialist care.
A common scenario is a patient who has had two flares in six months and is looking for recurrent flare control.
Another is a specialist clinic starting FMF treatment after a confirmed diagnosis.
Off-label use does happen, but it should stay with the prescriber who understands the risk profile.
Adults with gout flares or prevention needs
Adults are the main group for gout medicine use, especially when the aim is to reduce pain quickly or prevent another attack.
Colchicine is prescribed in both acute and preventive regimens.
Familial Mediterranean fever patients
FMF treatment relies on long-term use, often at divided doses.
For many patients, treatment is ongoing and may be lifelong.
Off-label and specialist use cases
Pericarditis is a recognised off-label use.
Specialists may also consider it in other inflammatory contexts, including studied cardiovascular adjunct use.
Available strengths, dosage forms and packaging
In the UK colchicine is supplied as 500 microgram (0.5 mg) tablets, usually in blister packs. Blister packs protect each dose from moisture and light and make it easier to spot missed doses, which matters with chronic medication.
How to take colchicine correctly for gout
For acute gout, the adult regimen is straightforward, but it must be followed carefully because the margin for error is small.
| Situation | Adult dose | Key point |
|---|---|---|
| Acute gout flare | 500 micrograms two to four times daily until symptoms are relieved | Maximum 6 mg in total per course |
| Prevention | 500 micrograms once or twice daily | Used as prophylaxis for recurrent flares |
| Repeat use | Do not repeat the acute course within 3 days | Reduces toxicity risk |
The first dose should be taken as soon as possible at the start of a flare.
If the medicine is being used for prevention, it should be taken regularly rather than only when pain appears.
Do not guess the dose from another person’s prescription, even if the tablets look identical.
Acute gout flare dosing
The adult acute regimen is 500 micrograms two to four times daily until symptoms are relieved, with no more than 6 mg in total per course.
Prevention dosing
For prophylaxis, 500 micrograms once or twice daily is the usual adult range.
That schedule is aimed at reducing recurrent flares rather than treating active pain.
Practical timing and repeat-use limits
Do not repeat the acute course within 3 days.
That rule is important because toxicity risk rises quickly if the medicine is taken too often.
Colchicine for Familial Mediterranean fever and other longer-term regimens
FMF can mean years of regular treatment, so patients want to know what long-term use looks like.
In that setting, colchicine treatment is usually divided through the day and continued for the long term.
- FMF
- A condition where colchicine may be used at 1.2–2.4 mg/day in divided doses.
- Long-term therapy
- Ongoing treatment that may be lifelong or as directed by the physician.
- Divided doses
- More than one dose per day to improve tolerability and maintain control.
| Use | Typical dose | Duration |
|---|---|---|
| FMF treatment | 1.2–2.4 mg/day | Lifelong or as directed by physician |
| Pericarditis | 0.5 mg once or twice daily | Specialist-directed |
Routine monitoring matters during chronic use because dose needs can change with kidney function, liver function and age.
That is also why FMF patients often stay in specialist follow-up.
Typical FMF dose range
The usual adult FMF range is 1.2–2.4 mg/day in divided doses.
Children with FMF may start lower, with careful titration.
Long-term treatment expectations
Many patients need continuous therapy rather than short courses.
That is very different from a one-off flare treatment.
Monitoring during chronic use
Long-term therapy should be reviewed regularly for tolerability and organ function.
The dose should be reviewed if it looks inconsistent with the patient’s age or comorbidities.
Dose adjustment and caution groups
Colchicine is not a medicine where standard dosing suits every patient.
Age, renal function and hepatic function can all change the safe dose.
| Group | Guidance | Key point |
|---|---|---|
| Children with FMF | Age 4 years and above: start 0.3–0.6 mg/day; titrate | Check indication and dose accuracy |
| Elderly patients | Lower initial dose; consider renal and liver function | Watch for sensitivity and interacting drugs |
| Mild to moderate renal impairment | Lower dose | Kidney function should be checked first |
| Severe renal impairment | Avoid | High toxicity risk |
| Mild to moderate hepatic impairment | Lower dose | Assess liver function carefully |
| Severe hepatic impairment | Avoid | Specialist review required |
Pregnant or lactating women also need careful risk assessment rather than routine supply.
Elderly patients
Older patients often need a lower starting dose.
They may also be more vulnerable to toxicity if they are already taking multiple medicines.
Renal impairment
Mild to moderate renal impairment usually means a lower dose.
Severe impairment is a clear avoid category.
Hepatic impairment and paediatric FMF use
Hepatic impairment also calls for dose reduction, with severe impairment avoided.
For paediatric FMF, children aged 4 years and above may start at 0.3–0.6 mg/day and be titrated carefully.
Contraindications and medicine interactions that matter most
Colchicine can become toxic if it is used in the wrong patient or alongside the wrong interacting medicine.
Severe renal or hepatic impairment, known hypersensitivity, and concomitant use with strong CYP3A4 inhibitors or P-gp inhibitors are absolute contraindications.
| Risk area | Why it matters | Action |
|---|---|---|
| Strong CYP3A4 inhibitors | Can raise colchicine levels and toxicity risk | Avoid without medical review |
| P-gp inhibitors | May increase exposure and adverse effects | Check all current medicines carefully |
| Renal impairment | Slower clearance and higher toxicity risk | Lower dose or avoid depending on severity |
| Hepatic impairment | Increased toxicity risk | Lower dose or avoid in severe cases |
High-risk patients include the elderly, people with gastrointestinal disease, and those taking multiple prescribed medicines.
Interaction checking is therefore especially important.
Absolute contraindications
Severe renal or hepatic impairment is an absolute stop.
Known hypersensitivity and incompatible interacting medicines are also absolute contraindications.
CYP3A4 and P-gp interaction risk
Strong CYP3A4 inhibitors and P-gp inhibitors can substantially increase toxicity risk.
A full medicine history is therefore essential.
Relative contraindications and high-risk patients
Mild to moderate renal or hepatic impairment, older age, gastrointestinal disease and pregnancy or lactation all need closer review.
These patients may still be treated, but only with the right prescriber oversight.
Side effects patients most commonly report
The most common side effects are gastrointestinal, but muscle pain and other systemic effects can also occur.
| Severity | Common effects | What to do |
|---|---|---|
| Mild | Diarrhoea, nausea, abdominal pain, vomiting | Seek advice if persistent or troublesome |
| Moderate | Fatigue, muscle pain, rash, haematological changes | Contact a pharmacist or prescriber |
In routine dosing, serious blood changes are rare, but they are taken seriously because colchicine has a narrow safety margin.
Overdose can be fatal, so patients should never treat “more pain” as a reason to take extra tablets.
Mild common effects
Diarrhoea, nausea, abdominal pain and vomiting are the effects most often mentioned first.
They may settle, but they should not be ignored if they become severe.
Moderate effects and when to seek advice
Fatigue, muscle pain and rash need review, especially if they appear after a medicine change.
Blood changes are rare in ordinary dosing but still matter clinically.
Rare but serious toxicity signals
Marked worsening of symptoms, dehydration or signs of systemic illness need urgent attention.
Because toxicity can be fatal, suspected overdose should never be managed at home.
Missed dose, overdose and emergency advice
Missed doses happen, especially when the medicine is taken on a long-term schedule.
The key is not to panic and not to double up.
- Take a missed dose as soon as remembered unless the next dose is near.
- Do not double doses.
- Seek emergency help for any suspected overdose.
- Contact NHS 111, your GP or emergency services if severe symptoms develop.
Overdose warning signs can include severe gastrointestinal distress and, in the worst cases, multi-organ failure.
If an adult has taken too much colchicine, emergency help should be sought immediately.
What to do if a dose is missed
Take it as soon as remembered unless the next dose is close.
Never make up for a missed dose by doubling the next one.
Overdose warning signs
Severe vomiting, diarrhoea and collapse are serious warning signs.
Multi-organ failure can occur in major toxicity.
When to contact NHS 111, GP or emergency services
NHS 111 is appropriate for urgent advice when symptoms are worrying but not immediately life-threatening.
Emergency services are needed for suspected overdose or major toxicity.
Storage and handling
Colchicine should be stored carefully because moisture, light and heat can reduce safe handling.
- Store at 15–30°C.
- Keep away from moisture and light.
- Leave tablets in the original packaging.
- Transport at controlled room temperature when travelling.
That original packaging matters because the patient, pharmacist and prescriber can all identify the exact product more easily.
For travel medication, the safest plan is to carry the labelled blister pack or bottle rather than loose tablets.
Home storage instructions
The home cupboard should be dry, cool and out of direct sunlight.
Bathroom storage is usually a bad idea because of humidity.
Travel and controlled room temperature
Short trips are usually fine if the medicine is kept at controlled room temperature.
Long exposure to heat should be avoided.
Keeping medicine safe in original packaging
Original packaging supports safe supply, correct identification and better expiry tracking.
It also makes it easier for a pharmacist to verify the product if there is a query.
Brand names and generics
In the UK colchicine is mostly supplied as generic 500 microgram tablets. Substitution is usually straightforward when the strength and formulation are comparable, but any switch should be checked with the pharmacist, especially after previous side effects.
The most important thing is not the label name but making sure the exact dose and medicine type are correct.
Legal status and availability in the UK
Colchicine is a prescription-only medicine (POM) in the UK.
Our online pharmacy can arrange colchicine with discreet delivery to the United Kingdom in 9–21 days, subject to prescription and supply checks.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Leeds | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Bristol | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Aberdeen | Scotland | 9–21 days |
| Leicester | England | 9–21 days |
| Exeter | England | 9–21 days |
Quick takeaway
Colchicine is a prescription-only MHRA approved medicine used mainly for gout, FMF and some specialist inflammatory conditions.
The key points are simple: get the dose right, check interactions carefully and use a proper pharmacy supply route.
For patients with gout flare treatment or long-term prophylaxis, the safest plan is the one that matches the prescription, the kidney and liver profile, and the intended indication.
